Astrana Health, Inc. (ASTH) fair value analysis

Nasdaq · Updated 2026-09-07

Astrana Health, Inc. is a healthcare company that provides managed care services and health insurance coverage to Medicare Advantage and Medicaid populations. The company operates across multiple states in the United States, delivering integrated healthcare services to its members.

Forward Fair Value verdict

Undervalued

Based on TickrTrends' weekly Forward Fair Value model, ASTH is trading at more than a 25% discount to estimated fair value.

ASTH currently ranks #7 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Undervalued for 3 consecutive weekly runs.

Last price: $35.91
Sector: Healthcare
12-month range: $22.32–$49.81

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: D
Leverage: High
RSI zone: Neutral
50/200-day trend: Mixed
52-week position: The lower-middle quarter of its range

What our data shows for ASTH

Our model validated 17 trailing price-to-earnings windows for ASTH, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $22.32–$49.81.
The 14-day relative strength index sits at a neutral 56.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for ASTH
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

What people are saying

Follow the ASTH conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — No material change this week: the verdict, bands and grades all held steady.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is ASTH stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), ASTH is trading at more than a 25% discount to estimated fair value and screens as undervalued. The exact fair value and discount are available to subscribers.

What is ASTH's TickrTrends verdict?

ASTH's current verdict is Undervalued, refreshed with every weekly Forward Fair Value run.

How does ASTH compare to other Healthcare stocks?

ASTH ranks #7 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is ASTH overbought or oversold?

ASTH's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

ASTH vs ADMA · ASTH vs ALGN · ASTH vs ANIP · ASTH vs AZN · ASTH vs BSX